PRGO
Healthcare · Drug Manufacturers - Specialty & Generic
Performance
PRGO (PRGO) Stock Analysis 2026
Rule-based · Updated daily · Not financial advice
PRGO (PRGO) operates in the Drug Manufacturers - Specialty & Generic space within the Healthcare sector. With a market cap of $1.5B, it qualifies as a small-cap company. Both revenue and profitability are declining, which raises questions about the durability of the current business model.
- Current ratio of 2.7× — ample short-term liquidity
- Dividend yield of 10.84% provides consistent income on top of price appreciation
- Price is near its 52-week low — potential entry point with asymmetric upside
- Low beta of 0.52 — less volatile than the market, suitable for conservative portfolios
- Revenue declined 7% YoY — warning sign for business momentum
- Negative profit margin of -43.5% — company is currently unprofitable
- Negative ROE of -52.2% — shareholder equity is being eroded
- High debt-to-equity of 153.22× increases financial risk, especially with elevated interest rates
Verdict
Hold
Mixed signals — strengths and risks roughly balance. Wait for a clearer catalyst.
AI Insight
Powered by ClaudeAI-generated analysis for informational purposes only. Not financial advice.
Related Articles
Revenue & Results
Dividends
Current DY
10.84%
5Y Avg Annual
$0.9372
Last Payment
$0.2900
Ex-Date
05/29/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest05/29/2026 | 06/16/2026 | $0.2900 | 10.73% |
03/02/2026 | 03/20/2026 | $0.2900 | 10.73% |
08/29/2025 | 09/16/2025 | $0.2900 | 10.73% |
05/30/2025 | 06/17/2025 | $0.2900 | 10.73% |
03/07/2025 | 03/25/2025 | $0.2900 | 10.73% |
11/29/2024 | 12/17/2024 | $0.2760 | 10.21% |
08/30/2024 | 09/17/2024 | $0.2760 | 10.21% |
05/31/2024 | 06/18/2024 | $0.2760 | 10.21% |
Magic Number
Shares needed to self-fund your next purchase
$10.81
Price
$0.2900
Last div. (semesterly)
38
shares
Own 38 PRGO shares ($410.78) and each semesterly dividend pays for 1 new share — the snowball runs on its own.
Investment target
$410.78
New shares / year
+2 shares
If You Had Invested…
Hypothetical return based on historical prices
* Dividend reinvestment calculated at ex-date price. For informational purposes only.
Earnings
Next Earnings
Jul 31, 2026
45
days
EPS (TTM)
$-12.93
P/E (TTM)
—
Fwd P/E
4.6
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Key Statistics
Valuation
Trading
Dividends
Profitability
Balance Sheet
Fair Value Estimates
Current price: $10.81
Graham Number
√(22.5 × EPS × Book Value)
N/A
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$16.89
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
5/10
56% score
Pays dividends
15Y hist.15+ years of dividend history
Dividend consistency (5Y+)
15 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
-52.2%Return on equity — measures how efficiently capital is used
Positive profit margin
-43.5%Net profit margin must be positive — company earns more than it spends
Revenue growth (annual)
-7.2%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
153.22×Low financial leverage reduces risk of distress
Current ratio above 1
2.72×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$32M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
10.84%Stock must distribute income to shareholders
Related Assets
Healthcare
About PRGO
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Location
Dublin, Ireland
Employees
8,100